Loading...
•
Jun 29, 2024
USANA Q2 2024 Earnings Report
USANA's Q2 2024 results were impacted by macroeconomic pressures and lower active customer counts.
Key Takeaways
USANA Health Sciences reported a decrease in net sales and diluted EPS for the second quarter of 2024 compared to the same period in 2023. The company is updating its fiscal year 2024 net sales and diluted EPS outlook due to these challenges.
Second quarter net sales were $213 million, down from $238 million in Q2 2023.
Second quarter diluted EPS was $0.54, compared to $0.89 in Q2 2023.
The company generated $8 million in operating cash flow and ended the quarter with $332 million in cash and cash equivalents.
Fiscal year 2024 net sales outlook is updated to $850 million to $880 million, and diluted EPS outlook is updated to $2.40 to $2.55.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company is updating its net sales and earnings per share outlook for fiscal year 2024, as follows: Consolidated Net Sales $850 - $880 million, Diluted EPS $2.40 - $2.55.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...